1-7 of 7
Rodolfo Bordoni
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

Clinical Trials & Observations
Jonathan W. Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J. M. Cline, Adrija Mamidipalli, Jingmin Liu, Alev Akyol, Christopher A. Yasenchak
Journal: Blood
Blood (2024) 143 (9): 786–795.
https://doi.org/10.1182/blood.2022019536
Published: 2024
Includes: Supplemental data
Journal Articles

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Christopher Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J. M. Cline, Shweta Jain, Jingmin Liu, Joseph Thaddeus Beck
Journal: Blood
Blood (2023) 142 (Supplement 1): 4435.
https://doi.org/10.1182/blood-2023-190260
Published: 2023
Journal Articles

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Christopher A. Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph V. Boccia, Vivian J.M. Cline, Adrija Mamidipalli, Jingmin Liu, Joseph T. Beck
Journal: Blood
Blood (2022) 140 (Supplement 1): 3685–3686.
https://doi.org/10.1182/blood-2022-156567
Published: 2022
Journal Articles

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Jerome Goldschmidt, MD, Ralph V. Boccia, MD, Vivian J.M. Cline, Mariana Sacchi, MD, Andres Forero-Torres, Robert B. Sims, MD, Jingmin Liu, Jonathan W. Friedberg, MD MSSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-136583
Published: 2020
Journal Articles

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Thomas Anderson, Timothy Larson, MD, Trevor Newhook, MS, Matthew Mei, MD, Linda Ho, Jonathan W. Friedberg, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 237.
https://doi.org/10.1182/blood-2019-124866
Published: 2019
Journal Articles

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Trevor Newhook, MS, Linda Ho, Matthew Mei, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2852.
https://doi.org/10.1182/blood-2019-122968
Published: 2019
Journal Articles

A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies

Amer M. Zeidan, MD, Rachel J. Cook, MD, Rodolfo Bordoni, MD, Ekaterine Asatiani, MD, Gongfu Zhou, Théa Faivre, Michael Byrne, MD, Michael R. Savona, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 640.
https://doi.org/10.1182/blood.V130.Suppl_1.640.640
Published: 2017